Who Owns Cardinal Health Nuclear & Precision Health Solutions?
Cardinal Health Nuclear & Precision Health Solutions is owned by Cardinal Health, a publicly traded American healthcare company headquartered in Dublin, Ohio. Cardinal Health Nuclear & Precision Health Solutions operates as a wholly-owned division of Cardinal Health, providing radiopharmaceuticals, nuclear pharmacy services, and precision medicine solutions to healthcare facilities across the United States.
Parent Company
Cardinal Health
Founded
2001
Status
Publicly Traded
Headquarters
Dublin, Ohio, USA
Who Owns Cardinal Health Nuclear & Precision Health Solutions?
- Parent Company: Cardinal Health
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: NYSE: CAH
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cardinal Health Nuclear & Precision Health Solutions | Cardinal Health | Brand division |
History of Cardinal Health Nuclear & Precision Health Solutions
- Founded: 2001
- Founders: Cardinal Health (internal development)
Cardinal Health Nuclear & Precision Health Solutions was established in 2001 as Cardinal Health's dedicated nuclear medicine and radiopharmaceutical division. The division was created to serve the growing demand for radiopharmaceuticals and nuclear pharmacy services from healthcare facilities across the United States.
Throughout the 2000s and 2010s, Cardinal Health Nuclear & Precision Health Solutions expanded its radiopharmaceutical portfolio and nuclear pharmacy network, becoming the largest radiopharmaceutical provider in the United States. The division developed specialized expertise in both PET and SPECT radiopharmaceuticals, providing comprehensive solutions for medical imaging and cancer treatment.
The division invested in advanced manufacturing capabilities, including cyclotrons for radiopharmaceutical production and state-of-the-art nuclear pharmacies for preparation and distribution. Cardinal Health Nuclear & Precision Health Solutions established itself as the only national US source for both PET and SPECT radiopharmaceuticals.
In recent years, Cardinal Health Nuclear & Precision Health Solutions has focused on advancing precision medicine through radiopharmaceutical innovation. The division has invested in proprietary technologies including Isotrac for dosing and labeling, and cloud-based department management software for healthcare facilities.
The division continues to expand its capabilities in radiopharmaceutical contract manufacturing and personalized medicine solutions, supporting pharmaceutical companies and healthcare providers in advancing cancer care and precision health initiatives.
About Cardinal Health
Cardinal Health operates through several key business segments focused on healthcare distribution and services. The Pharmaceutical segment distributes brand-name and generic pharmaceuticals to pharmacies, hospitals, and healthcare providers across the United States and internationally.
The Medical segment manufactures and distributes medical and surgical products, including gloves, surgical gowns, and other medical supplies. The company also operates nuclear pharmacies that prepare and deliver radiopharmaceuticals for medical imaging and cancer treatment.
Cardinal Health provides various healthcare technology solutions, including pharmacy management systems, supply chain management tools, and data analytics platforms. The company has expanded into at-home healthcare services, delivering medical supplies and pharmaceuticals directly to patients' homes.
Cardinal Health employs approximately 47,000 people worldwide and generates annual revenues exceeding $180 billion. The company serves pharmacies, hospitals, healthcare systems, and manufacturers across the United States and select international markets.
- Founded: 1971
- Headquarters: Dublin, Ohio, USA
- Company Type: Publicly Traded
- Stock: NYSE: CAH
- Revenue: approximately $226.0 billion (FY2025)
- Employees: Approximately 49,000
Where Is Cardinal Health Nuclear & Precision Health Solutions Made / Based?
- Headquarters: Dublin, Ohio, USA
- Manufacturing / Operations: United States
Cardinal Health Nuclear & Precision Health Solutions Sustainability & Ethics
Cardinal Health Nuclear & Precision Health Solutions operates within Cardinal Health's comprehensive healthcare sustainability framework, implementing environmental and ethical initiatives that align with the healthcare company's commitment to responsible radiopharmaceutical development and nuclear medicine practices. The division's Center for Theranostics Advancement in Indianapolis demonstrates leadership in sustainable precision medicine manufacturing and innovation.
Environmental Compliance and Safety: Cardinal Health Nuclear & Precision Health Solutions maintains strict adherence to Good Manufacturing Practices (GMP) regulations across all facilities. The division's facilities are designed with environmental control systems that ensure consistent and safe radiopharmaceutical production while minimizing environmental impact through advanced waste management and radiation safety protocols.
Sustainable Manufacturing Practices: The Commercial Manufacturing Center (CMC) within the Center for Theranostics Advancement implements sustainable manufacturing processes for theranostic radiopharmaceuticals. The facility supports the entire product lifecycle from development through commercial manufacturing at scale, emphasizing efficient resource utilization and minimal environmental footprint.
Radiation Safety and Environmental Protection: The division operates under strict Nuclear Regulatory Commission (NRC) licensing requirements, ensuring all facilities adhere to comprehensive radiation safety protocols. Cardinal Health Nuclear & Precision Health Solutions maintains advanced radiation protection systems and environmental monitoring to safeguard both workers and the community.
Precision Medicine Innovation Ethics: The division's theranostics development focuses on creating targeted treatments that may be less likely to harm healthy tissues than traditional treatments like radiation or chemotherapy. This precision approach demonstrates ethical commitment to patient safety while potentially offering better outcomes and quality of life.
Supply Chain Sustainability: Cardinal Health Nuclear & Precision Health Solutions operates the largest national network of nuclear pharmacies, enabling efficient distribution that minimizes transportation environmental impact. The division's strategic Indianapolis location allows reaching major U.S. population centers within 24 hours, optimizing logistics and reducing carbon footprint.
Community and Workforce Development: The Center for Theranostics Advancement was established in Indianapolis to leverage the region's strong pharmaceutical manufacturing workforce and experienced talent pool. The division contributes to local economic development while maintaining high standards for employee training and environmental stewardship.
Awards & Recognition
Cardinal Health Nuclear & Precision Health Solutions has received significant recognition for its innovation in theranostics, leadership in nuclear medicine, and commitment to advancing precision medicine, establishing itself as a pioneer in the rapidly growing radiopharmaceutical industry.
Theranostics Innovation Leadership: The Center for Theranostics Advancement has been acknowledged as a groundbreaking facility bringing together dozens of innovators, scientists, and manufacturers developing theranostic radiopharmaceutical products. The division's ability to track approximately 60 high-probability theranostics innovations demonstrates industry leadership in precision medicine development.
Manufacturing Excellence Recognition: The Commercial Manufacturing Center has been recognized for connecting early-phase drug development with commercial manufacturing at scale. This integrated approach supports the entire product lifecycle from development through patient delivery, setting industry standards for comprehensive radiopharmaceutical services.
Regulatory Compliance Achievement: Cardinal Health Nuclear & Precision Health Solutions has been acknowledged for maintaining strict compliance with both FDA and NRC regulations. The division's adherence to Good Manufacturing Practices and radiation safety protocols has been recognized as demonstrating exceptional commitment to quality and safety.
Market Leadership Recognition: The division has been acknowledged as a leader in the rapidly growing theranostics market, which is expected to grow from $4.3 billion to $12.7 billion by 2029. Cardinal Health Nuclear & Precision Health Solutions' strategic positioning in this expanding market has been recognized as driving industry growth and innovation.
Unit Dose Service Excellence: For over 25 years, Cardinal Health Nuclear & Precision Health Solutions has been recognized as the leader in unit dose radiopharmaceuticals. The division's Total Solution™ approach has been acknowledged as providing comprehensive services that distinguish it from mere dose providers.
Geographic Strategic Advantage: The division's Indianapolis location has been recognized for providing strategic advantages in supporting the radiopharmaceutical industry. The facility's ability to reach major U.S. population centers within 24 hours and access to world-class courier hubs has been acknowledged as optimizing patient access to critical treatments.
Workforce Development Recognition: Cardinal Health Nuclear & Precision Health Solutions has been acknowledged for leveraging Indianapolis's experienced pharmaceutical manufacturing workforce and talent pool. The division's contribution to local economic development and workforce expertise has been recognized as strengthening the regional healthcare ecosystem.
Cardinal Health Nuclear & Precision Health Solutions Recalls & Controversies
Cardinal Health Nuclear & Precision Health Solutions has maintained a strong operational record within Cardinal Health's healthcare portfolio, though the division faces challenges typical of the highly regulated radiopharmaceutical industry and the emerging theranostics market.
Regulatory Compliance Complexity: Operating in the radiopharmaceutical industry requires compliance with dual regulatory oversight from both the FDA and NRC. Cardinal Health Nuclear & Precision Health Solutions must navigate complex regulatory requirements while maintaining innovation and rapid response to emerging medical needs.
Radiation Safety Management: Handling radioactive materials and radiopharmaceuticals presents inherent risks regarding radiation exposure and environmental safety. The division faces ongoing challenges in maintaining zero-tolerance safety standards while expanding operations and developing new therapeutic applications.
Supply Chain and Distribution Challenges: The time-sensitive nature of radiopharmaceuticals creates significant logistical challenges, as many products have very short half-lives and require specialized handling. Cardinal Health Nuclear & Precision Health Solutions must balance speed with safety and regulatory compliance across its national distribution network.
Market Competition and Innovation Pressure: The rapidly growing theranostics market attracts increasing competition from other pharmaceutical companies and specialized radiopharmaceutical manufacturers. Cardinal Health Nuclear & Precision Health Solutions faces pressure to maintain its leadership position while investing in innovation and infrastructure.
Technology Implementation Risks: The division's significant investments in advanced manufacturing technologies and theranostics development carry inherent risks regarding technological obsolescence and implementation challenges. Cardinal Health Nuclear & Precision Health Solutions must manage these investments while maintaining operational efficiency.
Healthcare Cost Management: While theranostics offer promise for better patient outcomes, the high cost of developing and manufacturing precision radiopharmaceuticals creates challenges regarding healthcare affordability and reimbursement. The division faces ongoing scrutiny regarding cost-effectiveness and value-based healthcare delivery.
Workforce Specialization Challenges: The highly technical nature of radiopharmaceutical manufacturing and theranostics development requires specialized expertise that is in limited supply. Cardinal Health Nuclear & Precision Health Solutions faces ongoing challenges in recruiting and retaining qualified nuclear pharmacists, radiopharmaceutical scientists, and regulatory specialists.
Environmental Impact Concerns: Despite strict regulatory compliance, the division's use of radioactive materials and specialized manufacturing processes faces ongoing scrutiny regarding environmental impact and community safety. Cardinal Health Nuclear & Precision Health Solutions must maintain transparent communication about safety measures and environmental stewardship.
Brands Owned by Cardinal Health
- Cardinal Health At-Home - At-home healthcare solutions provider delivering medical supplies, equipment, an...
- Cardinal Health Specialty Pharmacy - Specialty pharmaceutical distribution and services provider serving specialty ph...
Cardinal Health Nuclear & Precision Health Solutions Ownership: Pros & Cons
Advantages
- +Only national US source for both PET and SPECT radiopharmaceuticals
- +Extensive network of 130+ nuclear pharmacies and 30+ cyclotrons
- +Advanced manufacturing and distribution capabilities
- +Proprietary technologies for precision, efficiency, and safety
- +Integration with Cardinal Health's broader pharmaceutical distribution network
- +Significant scale enabling reliable nationwide coverage
Considerations
- -Regulatory oversight of radiopharmaceutical manufacturing and distribution
- -Complex compliance requirements for nuclear medicine operations
- -Competition from other radiopharmaceutical providers
- -Dependency on Cardinal Health's supply chain and corporate policies
- -Pressure on margins from healthcare cost containment efforts
- -Limited flexibility in certain operational decisions due to corporate structure
Frequently Asked Questions About Cardinal Health Nuclear & Precision Health Solutions
Sources & Further Reading
- Cardinal Health Nuclear & Precision Health Solutions Official Website -
- Cardinal Health Nuclear Pharmacy Services -
- Center for Theranostics Advancement -
- U.S. Food and Drug Administration (FDA) -
- U.S. Nuclear Regulatory Commission (NRC) -
- Society of Nuclear Medicine and Molecular Imaging -
- Radiopharmaceutical Science Council -
- International Atomic Energy Agency (IAEA) -
- BCC Research Theranostics Market Analysis -
- American College of Radiology -
- Nuclear Pharmacy Commission -
- Radiopharmaceutical Market Reports -- Industry analysis publications
- Precision Medicine Journals -- Academic and research publications
- Nuclear Medicine Technology -- Industry technical publications
- Healthcare Distribution Alliance -
- Cardinal Health Investor Relations -
- NYSE: Cardinal Health (CAH) -
- SEC EDGAR: Cardinal Health -
Where to Buy
Disclosure: We may earn commission from purchasesCompetitors to Cardinal Health Nuclear & Precision Health Solutions
No direct competitors found in the same category. This could be because Cardinal Health Nuclear & Precision Health Solutionsoperates in a unique market segment or we're still building our competitor database.
Cardinal Health Stock Information
Jobs at Cardinal Health
Latest News About Cardinal Health Nuclear & Precision Health Solutions
Related Articles About Cardinal Health Nuclear & Precision Health Solutions
View more articlesMonthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.
A Complete Guide to LVMH Brands: What Does the Luxury Giant Own?
LVMH owns 75 luxury maisons including Louis Vuitton, Dior, Tiffany, Guerlain, and Sephora. Here is the complete brand list by division, with acquisition dates and what each brand does.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.